WFS’ new survey of 623 US-based physicians (15 specialties) shows that in orthopedic, the % of procedures expected to be postponed due to COVID-19 for both TKR and THR declined from 94% (Wave 1) to 85% (Wave 2). WFS MedTec: Updated Survey Data Points to Recovery by Q420
Of deferred spinal fusion procedures, surveyed surgeons now expect 74% of cases to be performed at a later date w/ 26% cancelling. Reasons for cancellation include pt seeking treatment w/ a different surgeon (26%) and underlying condition improving (23%). WFS MedTech Survey
Based on its survey of 623 US-based physicians across 15 specialties between April 27 and May 8, WFS notes that in general the % of robotic & laparoscopic procedures across all specialties declined compared to pre-COVID 19 levels, while the % of open procedures increased.
According to WFS’ physician survey w/ 49 orthopedic & 20 spine surgeons, robotic procedures during COVID-19 decreased compared to pre-COVID levels. Results were TKA 18% pre-COVID, 8% during COVID; THA 7% pre-COVID, 3% during-COVID; Spinal Fusion 5% pre-COVID, 3% during-COVID.
Surveyed surgeons report that 92% of their spinal fusions were performed in a hospital setting prior to COVID-19, dropping to 78% during the pandemic. ASC procedures have increased from 8% pre-pandemic to 11% during COVID-19. WFS MedTech Survey
WFS reports that surveyed surgeons believe it will take 3.4 months on avg until they are performing procedures at an equal or greater rate than prior to COVID-19. WFS MedTech Survey
A Wells Fargo Survey which included 49 ortho surgeons reported hip and knee replacements were down -97% from April 27 to May 8 due to COVID-19 w/ the percentage of procedures taking place in an ASC remaining steady and surgical consults dropping by -82% and -84%, respectively.
Ortho surgeons surveyed by Wells Fargo (n=49) expect 85% of knee and 89% of hip replacements postponed due to COVID-19 to be performed w/ the estimated time needed to perform surgeries at 2-3 mos. Many expect to lose pts to alternative treatments or to other surgeons.
In a new report, SmartTRAK provides estimates for COVID-19’s impact on US Joint Fluid Replacement and Regen Med Injectable markets in the short term. Impact of COVID-19 on the US Joint Fluid Replacement and Regenerative Medicine Injectable Markets for Knee OA
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis and impact by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to see more of SmartTRAK's latest COVID-19 coverage and resources, just click the button below.